December 10, 2009 15:30 ET

GeckoSystems Intl. (PINKSHEETS: GCKO) Will Be First to Mass Produce Personal Home Care Robot

LOS ANGELES, CA--(Marketwire - December 10, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that the journey for Martin Spencer, of GeckoSystems Intl. (PINKSHEETS: GCKO) is finally taking a long awaited next step. A step that has been nearly twelve years in the making.

Analogous to Henry Ford's transition from his garage based design of the Model-T before blazing a path with it to the assembly line, Martin Spencer is taking his personal companion home care robot, the CareBot from the recently announced "real world evaluation trials" into production.

The company that will be joining him on the historic journey has been identified as Sparton Corporation, who provides design and electronic manufacturing services, which include a range of engineering, pre-manufacturing and post-manufacturing services on a contract basis.

The news signals a milestone for GCKO, making them the world's first company to take a personal home healthcare robot into a mass production phase.

In order to put this news in perspective, BioMedReports reached out to Goldman Small Cap Research so they could help our readers understand the personal robotics market, stock price potential and give us an overview of the company's operations. Their full coverage report with a Speculative Buy rating and price target of $0.16 is available for immediate download and review.

The special news and coverage report is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556